查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症奈米技术市场：现况分析与预测（2023-2030）
市场调查报告书
商品编码
1346736

癌症奈米技术市场：现况分析与预测（2023-2030）

Cancer Nanotechnology Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计从 2023 年到 2030 年，癌症奈米技术市场的复合年增长率将达到约 13.8%。 奈米技术提供了一种直接、选择性地靶向癌细胞和肿瘤的方法。 这些工具使临床医生能够安全有效地对肿瘤进行化疗、放疗以及下一代免疫和基因疗法。 例如，根据 GLOBOCAN 2020 的数据，2020 年全球癌症患者人数增加至 1,930 万人，癌症死亡人数增加至 1,000 万人。 癌症盛行率的增加促进了癌症奈米技术市场的成长。 此外，旨在改善癌症治疗和解决罕见疾病的政府措施和政策也促进了市场成长。 2018年，科技部科学家开发了一种生物相容性多孔材料，作为一种多功能载体，无需使用内源性配体（离子或分子）即可将抗癌药物递送至肿瘤细胞核，并製备了聚二甲基硅氧烷（PDMS）奈米颗粒。 细胞核含有大部分遗传物质。 生物活性奈米粒子可以根据体内的因素或治疗改变其特性，可以充当体内状况的动态报告者，并提供有关疾病进展和治疗反应的空间和时间资讯。 因此，促进了癌症奈米技术市场的成长。

依类型划分，市场分为奈米粒子、奈米纤维、奈米棒、石墨烯、奈米流体装置等。 其中，奈米粒子占据了很大的市场份额。 这是因为增加药物传输装置和系统（例如奈米颗粒製剂）对于将药物输送到肺部至关重要。 奈米颗粒可以更好地将通常不溶的药物递送至局部和远处的肿瘤部位，从而减少通常与常规药物治疗相关的全身副作用。

根据应用，市场分为诊断、治疗和治疗诊断。 其中，诊断药物将在2022年拥有较高的市场份额，并将在预测期内继续占据主导地位。 这是因为奈米技术在医疗诊断和成像领域的日益采用正在推动市场需求的成长。 在生物医学研究中，奈米技术被广泛用于对抗 COVID-19。 就像许多使用奈米粒子作为基于封装某些药物活性成分的治疗的疫苗一样。 已发现许多奈米系统比其传统的对应物更适合用于治疗目的。 因此，这一因素正在推动市场成长。

依癌症类型，市场分为乳癌、胃癌、肺癌等。 其中，乳癌预计将在预测期内获得较高的市场份额。 由于用于乳癌治疗的奈米技术的广泛应用以及乳癌盛行率的迅速增加，乳癌在市场上占据了60%以上的份额。

为了更了解奈米药物的市场介绍，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、法国、义大利、西班牙、英国、欧洲其他地区）、亚太地区（中国、日本、印度和亚太地区的其他国家）根据其在世界各国的全球影响力进行分析。 由于多种因素，癌症奈米技术在北美越来越受欢迎。 由于癌症盛行率不断上升、医疗保健专业人员和公众对奈米技术的认识不断提高、先进成像技术的发展以及治疗选择的增加，北美癌症奈米技术市场预计将增长。 例如，根据 Cancer.net 的数据，2020 年估计有 586,202 人被诊断出患有甲状腺癌。

强生公司、GE Healthcare、Combimatrix Corporation (Invitae Corporation)、F. Hoffmann-La Roche、Sigma-Tau Pharmaceuticals Inc.、Merck and Company Inc.、辉瑞公司(Pfizer, Inc.)、Nanosphere, Inc. 併购和联盟也在发生。

目录

第 1 章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第 2 章研究方法或假设

  • 调查过程
  • 调查方法
  • 受访者简介

第 3 章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对癌症奈米科技市场的影响

第 6 章癌症奈米技术市场收入，2020-2030

第 7 章按类型划分的市场洞察

  • 奈米颗粒
  • 奈米纤维
  • 奈米棒
  • 石墨烯
  • 奈米流体装置
  • 其他

第 8 章按应用划分的市场洞察

  • 诊断
  • 治疗学
  • 治疗诊断学

第 9 章按应用划分的市场洞察

  • 乳癌
  • 胃癌
  • 肺癌
  • 其他

第 10 章按地区划分的市场洞察

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 亚太地区的其他国家/地区
  • 世界其他地区

第 11 章癌症奈米技术市场动态

  • 市场促进因素
  • 市场挑战
  • 影响分析

第 12 章癌症奈米科技市场机会

第 13 章癌症奈米科技市场趋势

第 14 章需求面与供给面分析

  • 需求方分析
  • 供给面分析

第 15 章价值链分析

第 16 章价格分析

第 17 章竞争场景

  • 竞争状况
    • 波特五力分析

第 18 章公司简介

  • Abbott
  • GE Healthcare
  • Combimatrix Corporation（Invitae Corporation）
  • Mallinckrodt Plc
  • Sigma-Tau Pharmaceuticals Inc.
  • Merck and Company Inc.
  • Pfizer, Inc.
  • Nanosphere, Inc.（Luminex Corporation）
  • Celgene Corporation
  • Teva Pharmaceutical Industries

第 19 章免责声明

简介目录
Product Code: UMHE212197

The cancer nanotechnology market is expected to register a CAGR of approx. 13.8% over the period of 2023-2030. Nanotechnology offers the means to target therapies directly and selectively for cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. For instance, according to GLOBOCAN, 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. This increasing prevalence of cancer contributes to the growth of the cancer nanotechnology market. Furthermore, government initiatives and policies aimed at improving cancer care and addressing rare diseases have contributed to the growth of the market. In 2018, Scientists at the Department of Science and Technology fabricated highly biocompatible porous polydimethylsiloxane (PDMS) nanoparticles as a versatile vehicle to deliver anti-cancer drugs to the nuclei of tumor cells without utilizing any intrinsic ligands (ions or molecules). The nucleus of any cell contains most of its genetic material. Bioactivatable nanoparticles that modify properties in reaction to factors or procedures within the body act as dynamic reporters of in vivo states and can provide both spatial and temporal information on disease progression and therapeutic response. Hence, boost the growth of cancer nanotechnology market.

Based on type, the market is segmented into nanoparticles, nanofibers, nanorods, graphene, nanofluidic devices, and others. Among these nanoparticles have a significant share of the market. This is because drug delivery devices and systems increased as nanoparticle drug formulations are vital in pulmonary drug delivery. The nanoparticles can deliver the normally insoluble drugs to local and distant tumor sites in a better way, thus reducing the systemic side effects generally associated with traditional drug therapies.

Based on application, the market is segmented into diagnostics, therapeutics, and theranostics. Among these, diagnostics has a high market share in 2022 and will dominate during the forecast period. This is due to the rise in the adoption of nanotechnology in medical diagnosis and imaging is increasing the market growth demand. In biomedical research, nanotechnology is widely used against COVID-19, as in numerous vaccinations that use nanoparticles as a treatment based on the encapsulation of the active ingredient of certain medications. Numerous nanosystems have been found to be better candidates for therapeutic purposes than conventional ones. Thus, this factor boosts market growth.

Based on the cancer type, the market is segmented into breast cancer, stomach cancer, lung cancer, and others. Among this breast cancer will attain a high market share during the forecast period. Breast cancer held more than 60% share in the market owing to the presence of wide range of nanotechnology for the management of breast cancer and the surge in the prevalence of breast cancer.

For a better understanding of the market adoption of nanomedicines, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. Cancer Nanotechnology has gained increasing popularity in North America due to various factors. The North America Cancer Nanotechnology market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of nanotechnology among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to Cancer.net, an estimated 586,202 people were diagnosed with thyroid cancer.

Some of the major players operating Johnson & Johnson, GE Healthcare, Combimatrix Corporation (Invitae Corporation), F. Hoffmann-La Roche, Sigma-Tau Pharmaceuticals Inc., Merck and Company Inc., Pfizer, Inc., Nanosphere, Inc. (Luminex Corporation), Celgene Corporation, and Teva Pharmaceutical Industries among others. Several M&A's along with partnerships have been undertaken.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the CANCER NANOTECHNOLOGY Market
  • 2.2. Research Methodology of the CANCER NANOTECHNOLOGY Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CANCER NANOTECHNOLOGY MARKET

6 CANCER NANOTECHNOLOGY MARKET REVENUE (USD Mn), 2020-2030F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Nanoparticles
  • 7.2. Nanofibers
  • 7.3. Nanorods
  • 7.4. Graphene
  • 7.5. Nanofluidic Devices
  • 7.6. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Diagnostics
  • 8.2. Therapeutics
  • 8.3. Theranostics

9 MARKET INSIGHTS BY APPLICATION

  • 9.1. Breast Cancer
  • 9.2. Stomach Cancer
  • 9.3. Lung Cancer
  • 9.4. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. UK
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. South Korea
    • 10.3.5. Rest of APAC
  • 10.4. Rest of the World

11 CANCER NANOTECHNOLOGY MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.1. Impact Analysis

12 CANCER NANOTECHNOLOGY MARKET OPPORTUNITIES

13 CANCER NANOTECHNOLOGY MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICE ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

  • 18.1. Abbott
  • 18.2. GE Healthcare
  • 18.3. Combimatrix Corporation (Invitae Corporation)
  • 18.4. Mallinckrodt Plc
  • 18.5. Sigma-Tau Pharmaceuticals Inc.
  • 18.6. Merck and Company Inc.
  • 18.7. Pfizer, Inc.
  • 18.8. Nanosphere, Inc. (Luminex Corporation)
  • 18.9. Celgene Corporation
  • 18.10. Teva Pharmaceutical Industries

19 DISCLAIMER